Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera ...
Natera, a leader in cfDNA testing, has shown impressive growth and is nearing profitability, but its current valuation appears overextended. The company's competitive landscape is intense, with rivals ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj ...
Jan 26 (Reuters) - Genetic-testing company Natera (NTRA.O), opens new tab convinced a jury in Delaware federal court on Friday that medical diagnostics rival CareDx's (CDNA.O), opens new tab AlloSure ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named to Fast Company’s 2025 Next Big Things in Techlist. Honored for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results